Cartesian Therapeutics, Inc. (RNAC) stock
RNACNasdaqPharmaceutical PreparationsFiscal year ends December 31
$6.08−0.27 (-4.25%)
Close on Nov 16, 2026Market cap $183.95MP/E –Yield –
Cartesian Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Cartesian Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$76.53M. For fiscal 2025 it was -$73.94M. The highest annual figure on record is $34.88M in fiscal 2020.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$73.94M | – |
| FY2024 | Dec 31, 2024 | -$23.67M | – |
| FY2023 | Dec 31, 2023 | -$51.16M | – |
| FY2022 | Dec 31, 2022 | -$31.63M | – |
| FY2021 | Dec 31, 2021 | -$60.38M | -273.1% |
| FY2020 | Dec 31, 2020 | $34.88M | – |
| FY2019 | Dec 31, 2019 | -$51.44M | – |
| FY2018 | Dec 31, 2018 | -$59.16M | – |
| FY2017 | Dec 31, 2017 | -$52.03M | – |
| FY2016 | Dec 31, 2016 | -$19.76M | – |
| FY2015 | Dec 31, 2015 | -$22.46M | – |
| FY2014 | Dec 31, 2014 | -$12.69M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$21.08M | – |
| Q1 FY2026 | Mar 31, 2026 | -$22.14M | – |
| Q4 FY2025 | Dec 31, 2025 | -$17.71M | – |
| Q3 FY2025 | Sep 30, 2025 | -$15.60M | -213.9% |
| Q2 FY2025 | Jun 30, 2025 | -$17.52M | – |
| Q1 FY2025 | Mar 31, 2025 | -$23.11M | – |
| Q4 FY2024 | Dec 31, 2024 | -$7.00M | – |
| Q3 FY2024 | Sep 30, 2024 | $13.69M | – |
| Q2 FY2024 | Jun 30, 2024 | -$14.45M | – |
| Q1 FY2024 | Mar 31, 2024 | -$15.92M | – |
| Q4 FY2023 | Dec 31, 2023 | -$23.29M | – |
| Q3 FY2023 | Sep 30, 2023 | -$9.22M | -311.7% |
| Q2 FY2023 | Jun 30, 2023 | -$9.90M | – |
| Q1 FY2023 | Mar 31, 2023 | -$8.77M | – |
| Q4 FY2022 | Dec 31, 2022 | -$11.85M | – |
| Q3 FY2022 | Sep 30, 2022 | $4.35M | – |
| Q2 FY2022 | Jun 30, 2022 | -$12.27M | – |
| Q1 FY2022 | Mar 31, 2022 | -$11.86M | – |
| Q4 FY2021 | Dec 31, 2021 | -$31.46M | – |
| Q3 FY2021 | Sep 30, 2021 | -$10.75M | -116.4% |
| Q2 FY2021 | Jun 30, 2021 | -$6.04M | – |
| Q1 FY2021 | Mar 31, 2021 | -$12.13M | – |
| Q4 FY2020 | Dec 31, 2020 | -$7.25M | – |
| Q3 FY2020 | Sep 30, 2020 | $65.64M | – |
| Q2 FY2020 | Jun 30, 2020 | -$11.81M | – |
| Q1 FY2020 | Mar 31, 2020 | -$11.70M | – |
| Q4 FY2019 | Dec 31, 2019 | -$12.88M | – |
| Q3 FY2019 | Sep 30, 2019 | -$11.12M | – |
| Q2 FY2019 | Jun 30, 2019 | -$7.20M | – |
| Q1 FY2019 | Mar 31, 2019 | -$20.24M | – |
| Q4 FY2018 | Dec 31, 2018 | -$12.75M | – |
| Q3 FY2018 | Sep 30, 2018 | -$16.03M | – |
| Q2 FY2018 | Jun 30, 2018 | -$16.97M | – |
| Q1 FY2018 | Mar 31, 2018 | -$13.41M | – |
| Q4 FY2017 | Dec 31, 2017 | -$12.66M | -954.3% |
| Q3 FY2017 | Sep 30, 2017 | -$15.44M | – |
| Q2 FY2017 | Jun 30, 2017 | -$8.61M | – |
| Q1 FY2017 | Mar 31, 2017 | -$15.32M | – |
| Q4 FY2016 | Dec 31, 2016 | $1.48M | – |
| Q3 FY2016 | Sep 30, 2016 | -$5.47M | – |
See a number that looks wrong?